Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianliebao is a Traditional Chinese Medicine (TCM) formulation developed by Guangdong Kangping Pharmaceutical Innovation Technology Development Co., Ltd. for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). The product is typically formulated as capsules containing a proprietary blend of herbal extracts, including *Vaccaria segetalis*, *Astragalus membranaceus*, *Plantago asiatica*, *Epimedium brevicornu*, and *Cibotium barometz*. Its therapeutic approach is based on TCM principles of tonifying the kidney, clearing heat, and promoting diuresis, which clinically manifests as anti-inflammatory, analgesic, and immunomodulatory effects. Qianliebao is used to alleviate symptoms such as urinary frequency, urgency, and pelvic pain by improving local blood circulation and reducing inflammation within the prostate gland.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qianliebao.